CDK20抗体,Rabbit Polyclonal CDK20 Antibody
  • CDK20抗体,Rabbit Polyclonal CDK20 Antibody
  • CDK20抗体,Rabbit Polyclonal CDK20 Antibody
  • CDK20抗体,Rabbit Polyclonal CDK20 Antibody

CDK20抗体;CDK20 Antibody—艾普蒂

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 上海
更新日期 2025-05-28
QQ交谈 微信洽谈

产品详情

中文名称:CDK20抗体英文名称:Rabbit Polyclonal CDK20 Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 7018 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Rabbit
偶联物: 靶点: CDK20
2025-05-28 CDK20抗体 Rabbit Polyclonal CDK20 Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 7018 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/25-1/100 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/5000-1/10000 Human,Mouse,Rat
   

产品详情

AliasesP42; CCRK; CDCH; PNQALRE
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenSynthetic peptide of human CDK20
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13034(CDK20 Antibody) at dilution 1/20. (Original magnification: ×200)    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13034(CDK20 Antibody) at dilution 1/20. (Original magnification: ×200)    


           

参考文献

以下是关于CDK20抗体的参考文献示例(注:以下内容为模拟示例,实际文献可能需要通过学术数据库检索确认):

---

1. **文献名称**: *"CDK20 promotes hepatocellular carcinoma progression via Wnt/β-catenin signaling and serves as a therapeutic target"*

**作者**: Jiang, L. et al.

**摘要**: 本研究开发了一种高特异性CDK20抗体,用于检测肝细胞癌(HCC)组织中CDK20的过表达。实验表明,CDK20通过激活Wnt/β-catenin通路促进肿瘤增殖,其抗体可用于预后评估及靶向治疗研究。

2. **文献名称**: *"Immunohistochemical analysis of CDK20 expression in colorectal cancer and its correlation with patient survival"*

**作者**: Smith, R. et al.

**摘要**: 通过商业化CDK20抗体进行免疫组化分析,发现结直肠癌中CDK20表达与肿瘤分期和患者生存率显著相关,提示其作为生物标志物的潜力。

3. **文献名称**: *"CDK20 inhibition suppresses neuroblastoma tumorigenesis through cell cycle arrest"*

**作者**: Tanaka, K. et al.

**摘要**: 利用CDK20特异性抗体阻断其功能,证实CDK20在神经母细胞瘤中通过调控G1/S期转换驱动肿瘤生长,为靶向干预提供依据。

4. **文献名称**: *"Development and validation of a novel CDK20 monoclonal antibody for molecular diagnostics"*

**作者**: Zhang, Y. et al.

**摘要**: 研究报道了一种新型CDK20单克隆抗体的开发与验证,该抗体在Western blot和免疫荧光中表现出高灵敏度和特异性,适用于基础研究与临床检测。

---

如需具体文献,建议通过 **PubMed** 或 **Web of Science** 检索关键词“CDK20 antibody”、“CDK20 immunohistochemistry”等获取最新研究。

       

背景信息

CDK20 (Cyclin-Dependent Kinase 20), also known as Cell Cycle-Related Kinase (CCRK), is a serine/threonine kinase involved in cell cycle regulation and transcriptional processes. It interacts with cyclins and regulates the activity of RNA polymerase II, impacting gene expression. CDK20 has gained attention due to its overexpression in cancers like hepatocellular carcinoma (HCC), colorectal cancer, and ovarian cancer, where it promotes tumor progression by activating oncogenic pathways such as Wnt/β-catenin. Its role in modulating immune responses and chemoresistance further highlights its therapeutic relevance.

CDK20 antibodies are critical tools for studying its expression, localization, and function in both normal and diseased tissues. These antibodies, often monoclonal or polyclonal, are designed to target specific epitopes of CDK20 and are validated for techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence. They help identify CDK20 as a potential biomarker for cancer diagnosis or prognosis. In therapeutic contexts, CDK20 antibodies may aid in developing targeted inhibitors or antibody-drug conjugates (ADCs). Preclinical studies suggest that blocking CDK20 activity could suppress tumor growth and enhance chemotherapy sensitivity. However, challenges remain in ensuring antibody specificity and minimizing off-target effects. Ongoing research aims to refine CDK20-targeting strategies for clinical translation.

       
关键字: CDK20抗体;CDK20;CDK20 Antibody;

公司简介

生物技术有限公司
成立日期 2024-07-02 (2年) 注册资本 20万人民币
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 抗体,植物生物技术,细胞培养,蛋白组学 经营模式 贸易,工厂,试剂,定制,服务
  • 上海切尔齐生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:20万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:生物试剂
  • 公司地址:青浦
询盘

CDK20抗体;CDK20 Antibody—艾普蒂相关厂家报价

产品名称 价格   公司名称 报价日期
¥1600.00
VIP10年
北京索莱宝科技有限公司
2025-11-24
¥1800
VIP1年
费雪(杭州)医学研究有限公司
2025-11-24
询价
VIP3年
维百奥(北京)生物科技有限公司
2025-10-27
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.